WallStreetZenWallStreetZen

NASDAQ: GLUE
Monte Rosa Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

GLUE earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$135.4M
Current Profit Margin
0%

GLUE Return on Equity

Current Company
-65.9%
Current Industry
-63.5%
Current Market
188%
GLUE's Return on Equity (-65.9%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when GLUE announces earnings.

GLUE Return on Assets

Current Company
-47.3%
Current Industry
2.9%
GLUE is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

GLUE Return on Capital Employed

Current Company
-52.5%
Current Industry
19.5%
GLUE has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

GLUE vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
GLUE$0.00-$128.79M-$135.35MN/AN/A
ADAP$60.28M-$102.70M-$113.87M+0.26%N/A
VNDA$192.64M$9.35M$2.51M-0.05%-39.66%
EPIX$0.00-$25.69M-$25.80MN/AN/A
NBTX$38.93M-$25.02M-$42.69M+58.68%N/A
View Top Biotech Stocks

GLUE earnings dates

Next earnings date
May 9, 2024

Monte Rosa Therapeutics Earnings & Revenue FAQ

What were GLUE's earnings last quarter?

On Invalid Date, Monte Rosa Therapeutics (NASDAQ: GLUE) reported Q4 2023 earnings per share (EPS) of -$0.57, up 9.52% year over year. Total Monte Rosa Therapeutics earnings for the quarter were -$33.25 million. In the same quarter last year, Monte Rosa Therapeutics's earnings per share (EPS) was -$0.63.

If you're new to stock investing, here's how to buy Monte Rosa Therapeutics stock.

What was GLUE's earnings growth in the past year?

As of Q2 2024, Monte Rosa Therapeutics's earnings has grown year over year. Monte Rosa Therapeutics's earnings in the past year totalled -$135.35 million.

What is GLUE's earnings date?

Monte Rosa Therapeutics's earnings date is Invalid Date. Add GLUE to your watchlist to be reminded of GLUE's next earnings announcement.

What was GLUE's revenue last quarter?

On Invalid Date, Monte Rosa Therapeutics (NASDAQ: GLUE) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Monte Rosa Therapeutics's revenue was $0.00.

What was GLUE's revenue growth in the past year?

As of Q2 2024, Monte Rosa Therapeutics's revenue has grown null year over year. Monte Rosa Therapeutics's revenue in the past year totalled $0.00.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.